Peptide Comparison

BPC-157 vs Larazotide

A detailed comparison to help you understand the differences and choose the right peptide for your research.

BP

BPC-157

Healing & Regeneration
VS
La

Larazotide

Gut Health

BPC-157 and Larazotide both support gut health but through very different mechanisms. BPC-157 promotes tissue healing and regeneration throughout the GI tract, while Larazotide specifically targets tight junctions to reduce intestinal permeability ('leaky gut'). Understanding these differences helps choose the right peptide for specific gut issues.

Quick Comparison

Aspect
BPC-157
Larazotide
Mechanism
Tissue healing, angiogenesis, growth factors
Tight junction regulation (zonulin inhibitor)
Primary Effect
Heals gut lining, reduces inflammation
Reduces intestinal permeability
Origin
Derived from human gastric juice protein
Synthetic zonulin peptide inhibitor
Clinical Stage
Extensive preclinical, limited human trials
Phase 3 clinical trials (celiac)
Target Conditions
Ulcers, IBD, NSAID damage, general gut health
Celiac disease, leaky gut specifically
Administration
Oral or injectable
Oral
Systemic Effects
Yes (healing throughout body)
Primarily gut-localized
Research Focus
Broad healing applications
Intestinal permeability specifically

Key Similarities

  • Both support gut barrier function
  • Both may help with gut-related conditions
  • Both can be taken orally
  • Both have research for inflammatory gut conditions
  • Both are generally well-tolerated
  • Both address aspects of 'leaky gut'

Key Differences

  • BPC-157 heals tissue; Larazotide tightens junctions
  • BPC-157 has systemic effects; Larazotide is gut-focused
  • Larazotide is further in clinical trials for celiac
  • BPC-157 addresses broader damage; Larazotide targets permeability
  • BPC-157 helps with ulcers and NSAID damage specifically
  • Larazotide specifically inhibits zonulin pathway

When to Choose Each

Choose BPC-157

Choose BPC-157 for general gut healing, ulcers, NSAID-induced damage, inflammatory bowel conditions, or when you want both gut and systemic healing benefits. It's the broader-acting option.

Choose Larazotide

Choose Larazotide specifically for intestinal permeability issues, celiac disease management, or when tight junction dysfunction is the primary concern. It's more targeted for leaky gut specifically.

Can You Stack Them?

BPC-157 and Larazotide could theoretically be combined since they work through different mechanisms—BPC-157 for healing and Larazotide for permeability. This combination might address gut issues comprehensively, though no studies have evaluated this specifically.

Frequently Asked Questions

Larazotide specifically targets intestinal permeability through tight junction regulation. BPC-157 may help through healing, but Larazotide is more targeted for the permeability aspect of leaky gut.
BPC-157 may help with gut healing, but Larazotide has specific clinical trial data for celiac disease symptom management. For celiac, Larazotide has more relevant research.
BPC-157 has more overall research but primarily preclinical. Larazotide has advanced further in human clinical trials specifically for celiac disease and intestinal permeability.

References

  1. Sikiric P, et al. "BPC 157 gastrointestinal effects." Curr Pharm Des, 2018. PMID: 29737246
  2. Leffler DA, et al. "Larazotide celiac trials." Gastroenterology, 2015. PMID: 26026393

Get the Complete Comparison Guide

Download our detailed comparison charts and decision framework.